A β-glucuronidase-responsive albumin-binding prodrug for potential selective kinase inhibitor-based cancer chemotherapy

European Journal of Medicinal Chemistry
2018.0

Abstract

We report on the synthesis and in vitro biological evaluations of a nanomolar protein kinase inhibitor (PKI) and its β-glucuronidase-responsive albumin-binding prodrug. The highly potent PKI is 400-3400 times more cytotoxic than the well-known PKI Roscovitine. The prodrug is able to bind covalently to human serum albumin through Michael addition and release the cytotoxic PKI in the presence of β-glucuronidase, an enzyme over-expressed in the microenvironment of solid tumours.

Knowledge Graph

Similar Paper

A β-glucuronidase-responsive albumin-binding prodrug for potential selective kinase inhibitor-based cancer chemotherapy
European Journal of Medicinal Chemistry 2018.0
Synthesis and Antitumor Efficacy of a β-Glucuronidase-Responsive Albumin-Binding Prodrug of Doxorubicin
Journal of Medicinal Chemistry 2012.0
Synthesis and biological evaluations of a monomethylauristatin E glucuronide prodrug for selective cancer chemotherapy
European Journal of Medicinal Chemistry 2013.0
A self-immolative dendritic glucuronide prodrug of doxorubicin
Med. Chem. Commun. 2011.0
Benzyl Ether-Linked Glucuronide Derivative of 10-Hydroxycamptothecin Designed for Selective Camptothecin-Based Anticancer Therapy
Journal of Medicinal Chemistry 2008.0
Study of a cyclopamine glucuronide prodrug for the selective chemotherapy of glioblastoma
European Journal of Medicinal Chemistry 2010.0
Synthesis and antitumor activity evaluations of albumin-binding prodrugs of CC-1065 analog
Bioorganic & Medicinal Chemistry 2008.0
Synthesis and biological evaluation of the suberoylanilide hydroxamic acid (SAHA) β-glucuronide and β-galactoside for application in selective prodrug chemotherapy
Bioorganic & Medicinal Chemistry Letters 2007.0
Development of dual-acting prodrugs for circumventing multidrug resistance
Bioorganic & Medicinal Chemistry Letters 2009.0
Probing the Cysteine-34 Position of Endogenous Serum Albumin with Thiol-Binding Doxorubicin Derivatives. Improved Efficacy of an Acid-Sensitive Doxorubicin Derivative with Specific Albumin-Binding Properties Compared to That of the Parent Compound
Journal of Medicinal Chemistry 2002.0